The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
|Slideshows|June 28, 2018
Psychiatry Rounds: The Children, Gaming, Candles in the Wind
Author(s)Laurie Martin
This month's roundup features noteworthy stories from around the web: the humanitarian crisis at the border, new gaming disorder diagnosis, a medication investigation of over 26,000 adult patients, a boundary-busting neurologist, and physician and celebrity suicides.
Advertisement
Advertisement
Related to this article
This study compared the efficacy and tolerability of the 5 second-generation antipsychotics that are currently FDA approved as adjunctive treatments for adults with MDD.
Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
TRD often mislabels depression; learn why MDD heterogeneity demands tailored treatments and when “difficult-to-treat” fits better.
First US TRD Awareness Day spotlights treatment-resistant depression, urging earlier recognition, stigma-breaking support, and renewed hope for patients and caregivers.
Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.
Advertisement
Advertisement
Trending on Psychiatric Times
1
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
2
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
3
The Psych Consult: TSH Testing in New-Onset Depression. An Endocrinologist’s Guidance for Psychiatrists
4
Comparison of Atypical Antipsychotics as Adjunctive Treatments for Major Depressive Disorder
5